Purchased 1,025,000 shares of common stock in the IPO directed share program at $16.00 per share
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Amit Etkin
Also a director
Chief Executive Officer
|
49 | Not stated | $2,188,487 | |
|
Nicholas Smith
PRESIDENT AND CFO
Title from the Form 4 dated Oct 2, 2026
|
37 | Not stated | $1,541,585 | |
|
Michael Hanley
Chief Operating Officer
|
53 |
Since 2024
2 years
|
$1,212,928 | |
|
Adam Savitz
Chief Medical Officer
|
60 |
Since 2021
5 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Mar 26, 2026 · updated by the 8-K of May 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Amit Etkin, M.D., Ph.D.
Board chair, CEO, Executive officer
|
49 |
2019
7 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Christopher Nixon Cox
Lead independent director
|
47 |
2022
4 years
|
Not stated |
Audit
|
High-Trend International Group (Nasdaq: HTCO) | $110,543 | |
|
Raymond Sanchez, M.D.
|
65 |
2025
1 year
|
Not stated | None stated | Rapport Therapeutics, Inc. (Nasdaq: RAPP) | $84,904 | |
|
Gwill York
|
69 |
2021
5 years
|
Not stated | None stated | Sofina SA | $88,178 | |
|
Andrew Dreyfus
|
67 |
2023
3 years
|
Not stated |
Audit
|
None stated | $80,263 | |
|
Husseini Manji, M.D.
|
67 |
2024
2 years
|
Not stated | None stated | None stated | $73,129 | |
|
Andrew Miller
Joined May 27, 2026
|
- | - | - | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Purchased 1,025,000 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 600,000 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 56,250 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 17,000 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 17,000 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 3,125 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 1,563 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 1,563 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 938 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 625 shares of common stock in the IPO directed share program at $16.00 per share
Purchased 2,536,354 shares issuable upon exercise of Pre-Funded Warrants in the 2025 private placement
Purchased 1,000,000 shares of common stock and 1,536,354 shares issuable upon exercise of Pre-Funded Warrants in the 2025 private placement
Purchased 1,606,358 shares of common stock in the 2025 private placement
Purchased 549,544 shares of common stock and 549,543 shares issuable upon exercise of Pre-Funded Warrants in the 2025 private placement
Loading...